Wrapping type plant polypeptide drug-loaded nanoparticles and preparation method thereof

Through the combined-type sustained-release plant polypeptide drug-loaded nanoparticle technology, the problems of poor water solubility and uncontrolled release in cancer treatment are solved, and the effective release of hydrophobic drugs and the improvement of treatment efficiency are achieved.

CN118903055AActive Publication Date: 2024-11-08WUHAN UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410914465.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-11-08
Estimated Expiration
2044-07-09

AI Technical Summary

Technical Problem

Traditional chemotherapy drugs have problems such as poor water solubility, lack of selectivity, great side effects, multidrug resistance and uncontrolled drug release in cancer treatment, resulting in damage to normal tissues and low treatment efficiency.

Method used

The drug-loaded nanoparticles of the recombinant sustained release plant peptides are prepared by cross-linking the monomers of the plant peptides and redox-sensitive structures in a mixed solution of alcohol and water to form the drug-loaded nanoparticles of redox-sensitive plant peptides and outside it The surface is coated with plant peptides to improve the water solubility and sustained release properties of the drug.

Benefits of technology

The effective release of hydrophobic drugs is achieved, the toxicity of drugs to the human body is reduced, the treatment efficiency is improved, and the stable and long-term drug release performance is shown under simulated human conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903055A_ABST
    Figure CN118903055A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedical polymers, in particular to a compound-wrapping type slow-release plant polypeptide drug-loaded nano-particle and a preparation method thereof, and the drug-loaded nano-particle is compound-wrapped by plant polypeptide through electrostatic adsorption and crosslinking. The plant polypeptide drug-loaded nanoparticles have oxidation-reduction sensitive response capability and can be released at a specified position, so that the toxicity of the drug to a human body is reduced, and the treatment effect of the drug is improved. The wrapping type slow-release plant polypeptide drug-loaded nanoparticles have certain slow-release capability, and can be widely applied to controlled release of drugs, tissue engineering, gene therapy and the like when being prepared from natural polymers. The preparation method disclosed by the invention is simple to operate and stable in quality, and the prepared drug-loaded nanoparticles are controllable in particle size, concentrated in dispersity, good in stability and suitable for mass production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biomedical macromolecules, and in particular to a kind of coated plant polypeptide drug-carrying nanoparticles and a preparation method thereof. Background Art

[0002] Chemotherapy is currently the main treatment for cancer. Chemotherapy can treat some local and metastatic cancers and can be used alone or in combination with other forms of treatment. Traditional chemotherapeutic drugs have certain particularities in actual clinical applications, such as: traditional chemotherapy drugs have extremely poor water solubility, and many traditional chemotherapy drugs need to be used in conjunction with their corresponding solvents, which increases the burden of the drugs on the human body and increases side effects; lack of selectivity, traditional chemotherapy drugs will not only inhibit cancer cells but also affect rapidly growing normal human cells, leading to the death of normal human cells; multidrug resistance is generated, which is mainly due to the increase of efflux pumps in the cell membrane, which are responsible for transporting various anticancer drugs out of the cell. In fact, the damage of chemotherapy drugs to normal tissues and organs of the human body is an important factor leading to the high mortality rate of cancer patients.

[0003] Most available anticancer drugs are highly toxic, such as paclitaxel, cyclophosphamide, and doxorubicin DOX. These drugs are administered systemically to patients, and their indiscriminate cytotoxicity limits the drug concentration that can accumulate in tumor tissue. Although smart drug controlled release systems have been studied for cancer treatment over the past few decades, only a few have been approved and entered clinical trials. The key issues that need to be addressed include: lack of sufficient drug loading, appropriate drug release kinetics at the lesion site, low cellular uptake, drug accumulation in off-target organs (such as the liver and spleen), insufficient drug release, and lack of control over the drug release pattern.

[0004] In the past few years, in order to solve these problems of the currently used controlled drug release systems, various controlled drug release systems have been studied and designed to better control drug release, including increasing drug accumulation at the tumor site through passive, active and sensitive response mechanisms; using appropriate stimulation to control the release of loaded drugs; releasing loaded drugs at a controlled rate for a sufficiently long time; and circulating in the blood for at least 24-30 hours before reaching the tumor, during which time the drug should be released slowly. Through these methods, controlled drug release systems can partially solve the two main problems associated with traditional drug release systems: burst release and uncontrolled release of drugs. In addition to controlling the drug concentration at the effective concentration required for treatment, it can also reduce the damage of drugs to normal tissues and reduce the frequency of administration, thereby potentially improving patient compliance with drugs.

[0005] Therefore, it is necessary to develop a peptide drug-loaded nanoparticle that can be used to release hydrophobic drugs, reduce drug damage to normal tissues, and reduce the frequency of drug administration. Summary of the invention

[0006] The purpose of the present invention is to provide a coated sustained-release plant polypeptide drug-loaded nanoparticle, which is prepared by coating the plant polypeptide on the outer surface of the redox-sensitive plant polypeptide drug-loaded nanoparticle, and can be used for the release of hydrophobic drugs, improve the water solubility of hydrophobic drugs, have a certain sustained-release ability, reduce the toxicity of the drug to the human body, and improve the therapeutic efficiency of the drug.

[0007] In order to achieve the above object, the present invention adopts the following technical solution:

[0008] In a first aspect of the present invention, a coated sustained-release plant polypeptide drug-loaded nanoparticle is provided, wherein the coated sustained-release plant polypeptide drug-loaded nanoparticle is prepared by coating the plant polypeptide on the outer surface of the redox-sensitive plant polypeptide drug-loaded nanoparticle;

[0009] The redox-sensitive plant polypeptide drug-loaded nanoparticles are prepared by using plant polypeptides and hydrophobic drugs as raw materials, introducing redox-sensitive monomers, using a mixed solution of alcohol and water as solvent, and under the action of a cross-linking agent.

[0010] Preferably, in the coating, the mass ratio of the plant polypeptide to the redox-sensitive plant polypeptide drug-loaded nanoparticles is in the range of 3-6:20. If the ratio is too low, effective coating cannot be formed, and if the ratio is too high, the particle size of the drug-loaded nanoparticles will be too large, which is not conducive to drug delivery.

[0011] Preferably, the plant polypeptide comprises at least one of millet polypeptide, soybean polypeptide, peanut polypeptide and corn polypeptide. The millet polypeptide, soybean polypeptide, peanut polypeptide and corn polypeptide can be directly purchased as commercial products.

[0012] Preferably, the hydrophobic drug includes at least one of doxorubicin or its hydrochloride, erlotinib or its hydrochloride, curcumin or its hydrochloride, paclitaxel or its hydrochloride, methotrexate or its hydrochloride, and ibuprofen or its hydrochloride.

[0013] Preferably, the monomer of the redox sensitive structure includes at least one of cystamine hydrochloride, dithiodipropionic acid, diacrylamide, and dithiodicarboxylic acid.

[0014] In the second aspect of the present invention, a method for preparing the coated sustained-release plant polypeptide drug-loaded nanoparticles is provided, the method comprising the following steps:

[0015] S1. Mix the plant polypeptide and the aqueous solution containing the redox-sensitive structural monomer, adjust the pH to 8.0-9.0, and continue the reaction until the reaction is complete to obtain a mixed system;

[0016] S2, adding an alcohol solution of a hydrophobic drug to the mixed system and mixing well, and then adding a cross-linking agent until the reaction is complete to obtain a product;

[0017] S3. After removing the alcohol solution from the product, the product is filtered, the remaining system is centrifuged, the supernatant is taken, and the supernatant is freeze-dried to obtain redox-sensitive plant polypeptide drug-loaded nanoparticles.

[0018] S4, dissolving the redox-sensitive plant polypeptide drug-loaded nanoparticles in an alcohol solution, adding the plant polypeptide and the cross-linking agent, stirring evenly, and continuing the reaction;

[0019] S5. After the reaction is completed, the insoluble matter is precipitated after the alcohol solution is removed. The remaining system after filtration is centrifuged and the supernatant is removed and freeze-dried to obtain the coated plant polypeptide drug-loaded nanoparticles.

[0020] Furthermore, when the hydrophobic drug is in the form of a hydrochloride salt, the step S2 specifically comprises:

[0021] The alcohol solution of the hydrophobic drug is added to the mixed system and mixed evenly, and then a cross-linking agent is added, and the pH of the solution is adjusted to 8.0-9.0 and the reaction is continued until the reaction is complete to obtain a product.

[0022] Sodium hydroxide or potassium hydroxide can be used to adjust the solution pH to 8.0-9.0.

[0023] Preferably, the mass ratio of the hydrophobic drug to the plant polypeptide is 1-8:20. If the mass ratio is too small, the drug content in the drug-loaded nanoparticles cannot meet the actual use requirements; if the mass ratio is too large, the drug cannot be completely encapsulated, resulting in a large loss.

[0024] Preferably, in the step S1, the ratio of the monomer containing a redox-sensitive structure to the plant polypeptide is in the range of 2-8:20. If the ratio is too small, the sensitivity to redox is not significant; if the ratio is too large, it is not conducive to the encapsulation of hydrophobic drugs and the formation of drug-loaded nanoparticles. Preferably, in the step S1, the mass ratio of the monomer containing a redox-sensitive structure to the plant polypeptide is 2-8:20. If the mass ratio is too small, the redox performance of the drug-loaded nanoparticles is not significant; if the mass ratio is too large, the drug encapsulation performance of the drug-loaded nanoparticles decreases and the structural stability decreases.

[0025] The concentration of the aqueous solution containing the redox-sensitive structural monomer is in the range of 1 mg / mL to 4 mg / mL (preferably 2 mg / mL).

[0026] In the above technical solution, in step S1, the plant polypeptide and the aqueous solution containing the redox-sensitive structural monomer are mixed, and the pH of the solution is adjusted to 8.0-9.0 using sodium hydroxide or potassium hydroxide, and then the reaction is continued until the reaction is complete to obtain a mixed system;

[0027] This is because the hydrochloric acid on the redox-sensitive structural monomer needs to be removed to expose the reactive groups, so the pH of the solution needs to be adjusted to 8.0-9.0.

[0028] Preferably, in step S2, the cross-linking agent is glutaraldehyde, and the ratio of the cross-linking agent to the plant polypeptide is between 10 μL / 20 mg and 100 μL / 20 mg. If the ratio is too small, the structure of the drug-loaded nanoparticles cannot be well formed and the structure is relatively loose; if the ratio is too large, the carrier cross-linking degree is large and dense, and the drug cannot be well encapsulated and released.

[0029] Preferably, in step S2, the alcohol solution is an ethanol aqueous solution, and the volume ratio of water to ethanol in the ethanol aqueous solution is 1:2-4. If the volume ratio is too small, the hydrophobic drug will precipitate from the water, and the drug loading will decrease; if the volume ratio is too large, the solubility of the polypeptide carrier will decrease, resulting in a decrease in yield.

[0030] Preferably, when the hydrophobic drug is in the form of a hydrochloride salt, the step S2 specifically comprises:

[0031] The alcohol solution of the hydrophobic drug is added to the mixed system and mixed evenly, and then a cross-linking agent is added. The pH of the solution is adjusted to 8.0-9.0 with sodium hydroxide or potassium hydroxide, and then the reaction is continued until the reaction is complete to obtain a product.

[0032] This is because the hydrochloric acid on the hydrochloride drug needs to be removed to expose the reactive groups, so the solution pH needs to be adjusted to 8.0-9.0.

[0033] Preferably, when the monomer containing a redox-sensitive structure and the hydrophobic drug are both in the form of hydrochloride, the pH should be adjusted to 8.0-9.0 after the introduction of the monomer containing a redox-sensitive structure, and the hydrophobic drug should be added to adjust the pH after a period of reaction. This is because the carrier needs to be formed first and then the drug is encapsulated. Reversing the order or adding them at the same time is not conducive to drug encapsulation.

[0034] Preferably, in step S2, the alcohol solution of the hydrophobic drug is added dropwise to the mixed system of step S1 at a dropping speed of 1-2 mL / min.

[0035] Preferably, the dehydrated dry particle size range of the plant polypeptide drug-loaded nanoparticles under a transmission electron microscope is 30-50 nm, and the hydrated particle size range of the plant polypeptide drug-loaded nanoparticles under a dynamic light scattering analyzer is 100 nm-360 nm.

[0036] Plant peptides are natural macromolecules that have excellent compatibility with human tissues. After entering the human body, under the action of microorganisms or enzymes, the molecular chains break and degrade, and are eventually converted into monomers in the body or metabolized into water and carbon dioxide.

[0037] Preferably, in step S4, the ratio of the volume of the cross-linking agent to the mass of the plant polypeptide is in the range of 2-4 μL / mg.

[0038] Preferably, in step S4, the cross-linking agent includes at least one of glutaraldehyde, glyoxal and o-phthalaldehyde.

[0039] Preferably, in step S4, the mass ratio or mass-to-volume ratio of the redox-sensitive plant polypeptide drug-loaded nanoparticles to the alcohol solution is 9-11 mg / mL, the alcohol solution is ethanol, and the volume ratio of water to ethanol is 1:2-4.

[0040] The present invention has the following advantages and beneficial effects:

[0041] 1. The coated sustained-release plant polypeptide drug-loaded nanoparticles of the present invention are prepared by coating the plant polypeptide on the outer surface of the redox-sensitive plant polypeptide drug-loaded nanoparticles. The plant polypeptide and the redox-sensitive plant polypeptide drug-loaded nanoparticles have electrostatic adsorption and cross-linking effects, so that the prepared coated drug-loaded nanoparticles have good stability, producing an unexpected technical effect: they show stable and long-lasting drug release performance in PBS containing 10μM GSH that simulates normal human tissue.

[0042] 2. The coated plant polypeptide drug-loaded nanoparticles of the present invention can not only improve the water solubility of hydrophobic drugs, reduce the toxicity of drugs to the human body, and improve the therapeutic efficiency of drugs; but also provide sustained-release properties, releasing the loaded drugs at a controllable rate over a sufficiently long period of time.

[0043] 3. The coated plant polypeptide drug-loaded nanoparticles of the present invention still retain the excellent performance of the drug-loaded nanoparticles after coating. The preparation method is simple to operate, and the drug-loaded nanoparticles are coated with the plant polypeptide itself, with stable quality. The prepared drug-loaded nanoparticles have controllable particle size, concentrated dispersion, good stability, and are suitable for mass production. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 This is the hydrated particle size distribution diagram of the millet polypeptide-doxorubicin coated drug-loaded nanoparticles prepared in Example 1;

[0045] Figure 2 This is a stability diagram of millet polypeptide-doxorubicin coated drug-loaded nanoparticles prepared in Example 1;

[0046] Figure 3 This is a transmission electron microscopy image of the millet polypeptide-doxorubicin coated drug-loaded nanoparticles prepared in Example 1;

[0047] Figure 4 The in vitro drug release performance of the millet polypeptide-doxorubicin drug-loaded nanoparticles prepared in Example 1, wherein the groups in the figure are PBS, ABS, PBS containing 10 μM GSH, PBS containing 10 mM GSH, and ABS containing 10 mM GSH;

[0048] Figure 5 The in vitro drug release performance of the millet polypeptide-doxorubicin coated drug-loaded nanoparticles prepared in Example 1; the groups in the figure are PBS, ABS, PBS containing 10 μM GSH, PBS containing 10 mM GSH, and ABS containing 10 mM GSH;

[0049] Figure 6 The toxicity of the coated millet polypeptide nanoparticles prepared in Example 1 to NCI-H1299 cells and MCF-10A cells;

[0050] Figure 7 The toxicity of the millet polypeptide-doxorubicin-coated drug-loaded nanoparticles prepared in Example 1 to NCI-H1299 cells;

[0051] Figure 8 The toxicity of the millet polypeptide-doxorubicin-coated drug-loaded nanoparticles prepared in Example 1 to MCF-10A cells;

[0052] Fig. 9 This is the hydrated particle size distribution diagram of millet polypeptide-doxorubicin complexed drug-loaded nanoparticles prepared in Comparative Example 2;

[0053] Fig.10 This is a stability diagram of millet polypeptide-doxorubicin coated drug-loaded nanoparticles prepared in Comparative Example 2;

[0054] Fig.11 The in vitro drug release performance of the millet polypeptide-doxorubicin complexed drug-loaded nanoparticles prepared in Comparative Example 2, wherein the groups in the figure are PBS, ABS, PBS containing 10 μM GSH, PBS containing 10 mM GSH, and ABS containing 10 mM GSH. DETAILED DESCRIPTION

[0055] For a better understanding of the present invention, the following examples are provided to further illustrate the present invention, but the present invention is not limited to the following examples.

[0056] Example 1

[0057] Step S1, prepare a 2 mg / mL cystamine hydrochloride aqueous solution, adjust its pH value to 8 using a 0.1 M NaOH aqueous solution, weigh 20 mg of millet polypeptide, add 2 mL of the prepared cystamine aqueous solution, stir evenly with a magnetic stirrer to obtain a mixed system;

[0058] Step S2, preparing a 1.5 mg / mL doxorubicin hydrochloride ethanol solution, slowly dripping 4 mL of the doxorubicin hydrochloride ethanol solution into the mixed system, adding a certain amount of 2.5 wt % glutaraldehyde after stirring evenly, and then continuing to stir for 6 hours, then dripping a 0.1 M NaOH aqueous solution to adjust the pH to 8, and stirring for 24 hours to obtain the product;

[0059] Step S3, vacuum-removing ethanol from the product, centrifuging it, and lyophilizing the supernatant to obtain millet polypeptide drug-loaded nanoparticles (i.e., redox-sensitive plant polypeptide drug-loaded nanoparticles).

[0060] Step S4: Take 20 mg of the prepared millet polypeptide drug-loaded nanoparticles, add 2 mL of deionized water and 4 mL of ethanol, stir evenly with a magnetic stirrer, add 3 mg of millet polypeptide, stir for 24 h, then add 9 μL of glutaraldehyde and react for another 24 h.

[0061] Step S5: After the reaction is completed, the ethanol is removed by vacuum, and the supernatant is taken out for lyophilization after centrifugation to obtain the coated plant polypeptide drug-loaded nanoparticles.

[0062] The hydrated particle size distribution of the millet polypeptide-doxorubicin-coated drug-loaded nanoparticles prepared in Example 1 is shown in FIG. Figure 1 shown; from Figure 1 It can be seen that the hydrated particle size of millet polypeptide-doxorubicin drug-loaded nanoparticles is 392nm.

[0063] The stability of the millet polypeptide-doxorubicin coated drug-loaded nanoparticles prepared in Example 1 is as follows Figure 2 shown; from Figure 2 It can be seen that within the measured 96 hours, the particle size and distribution of the drug-loaded nanoparticles changed little, and had good stability.

[0064] The transmission electron microscopy image of the millet polypeptide-doxorubicin coated drug-loaded nanoparticles prepared in Example 1 is as follows: Figure 3 As shown; the millet polypeptide-doxorubicin drug-loaded nanoparticles have regular spherical morphology, and the dry particle size is about 52nm.

[0065] The in vitro drug release performance of the uncoated millet polypeptide-doxorubicin drug-loaded nanoparticles prepared in Example 1 is as follows: Figure 4As shown, it can be seen that the drug release rate of the uncoated millet polypeptide-doxorubicin drug-loaded nanoparticles changes significantly when the pH environment and GSH concentration change, showing good dual sensitivity to pH and redox.

[0066] The in vitro drug release performance of the millet polypeptide-doxorubicin-coated drug-loaded nanoparticles prepared in Example 1 is as follows Figure 5 As shown. Figure 5 It can be seen that the coated drug-loaded nanoparticles can effectively release drugs, showing a stable and long-lasting drug release performance, and effectively retaining the redox and pH dual response characteristics of the drug-loaded nanoparticles. The release rate in the 10mM GSH environment is faster than that in the 10μM GSH environment, and the release rate in the acidic environment is faster than that in the neutral environment.

[0067] The toxicity of the coated millet polypeptide nanoparticles prepared in Example 1 to NCI-H1299 cells and MCF-10A cells is as follows Figure 6 As shown. Figure 6 It can be clearly observed that millet polypeptide nanoparticles exhibit extremely low cytotoxicity.

[0068] The toxicity of the millet / soybean peptide-doxorubicin drug-loaded nanoparticles prepared in Example 1 to NCI-H299 cells before and after coating (MP-ss@DOX is before coating, MPB-ss@DOX is after coating) is shown in Figure 2. Figure 7 As shown. Figure 7 It can be seen that millet polypeptide-doxorubicin coated drug-loaded nanoparticles have a good growth inhibitory effect on NCI-H299 cells.

[0069] The toxicity of the millet polypeptide-doxorubicin-coated drug-loaded nanoparticles prepared in Example 1 to MCF-10A cells before and after coating is as follows: Figure 8 As shown. Figure 8 It can be seen that millet polypeptide-doxorubicin drug-loaded nanoparticles have a certain inhibitory effect on the toxicity of DOX.

[0070] It can be seen from the above that in Example 1, electrostatic adsorption and cross-linking act together, and the obtained coated drug-loaded nanoparticles have good stability and show stable and long-lasting drug release performance in PBS containing 10 μM GSH simulating normal human tissue.

[0071] Comparative Example 1

[0072] In this comparative example, except that no crosslinking agent is added in the wrapping step, which is different from Example 1, the other steps are the same as Example 1, and the specific operations are as follows:

[0073] A 2 mg / mL cystamine hydrochloride aqueous solution was prepared, and its pH value was adjusted to 8 using a 0.1 M NaOH aqueous solution, a 1.5 mg / mL doxorubicin hydrochloride ethanol solution was prepared, 20 mg millet polypeptide MP was weighed, 2 mL of the prepared cystamine aqueous solution was added, and after stirring evenly with a magnetic stirrer, 4 mL of doxorubicin hydrochloride ethanol solution was slowly dripped in at a certain rate, and after stirring evenly, a certain amount of 2.5 wt% glutaraldehyde was added, and after reacting for 6 hours, a 0.1 M NaOH aqueous solution was added to adjust the pH to 8, and stirring was continued for 24 hours, and then 5 mg millet polypeptide was added and stirred for 48 hours. After the reaction was complete, ethanol was removed in vacuo, and the mixture was centrifuged by a centrifuge, and the supernatant was lyophilized to obtain the coated sustained-release plant polypeptide drug-loaded nanoparticles.

[0074] Comparative Example 2

[0075] The difference between this comparative example and Example 1 is that millet polypeptide and glutaraldehyde are added before freeze-drying. The specific operation steps are as follows:

[0076] Step S1, prepare a 2 mg / mL cystamine hydrochloride aqueous solution, adjust its pH value to 8 using a 0.1 M NaOH aqueous solution, weigh 20 mg millet polypeptide MP, add 2 mL of the prepared cystamine aqueous solution, stir evenly with a magnetic stirrer, and obtain a mixed system;

[0077] Step S2, prepare 1.5 mg / mL doxorubicin hydrochloride ethanol solution, slowly drip 4 mL of doxorubicin hydrochloride ethanol solution at a certain rate, stir evenly, add a certain amount of 2.5 wt% glutaraldehyde, react for 6 hours, add 0.1 M NaOH aqueous solution to adjust the pH to 8, continue stirring for 24 hours to obtain the product.

[0078] Step S3, add 5 mg millet polypeptide to the product and stir for 24 hours, then add 15 μL glutaraldehyde and react for 24 hours.

[0079] Step S4, then remove the ethanol in vacuo, centrifuge, and freeze-dry the supernatant to obtain the coated sustained-release plant polypeptide drug-loaded nanoparticles.

[0080] The hydrated particle size distribution diagram of the millet polypeptide-doxorubicin-coated drug-loaded nanoparticles prepared in Comparative Example 2 is shown in Fig. 9 shown; from Fig. 9 It can be seen that the hydrated particle size of soybean peptide-doxorubicin drug-loaded nanoparticles is 232.5 nm.

[0081] The stability of millet polypeptide-doxorubicin coated drug-loaded nanoparticles prepared in comparative example 2 is shown in the figure below: Fig.10 shown; from Fig.10 It can be seen that within the measured 96 hours, the particle size and distribution of the drug-loaded nanoparticles changed little, and had good stability.

[0082] The in vitro drug release performance of the millet polypeptide-doxorubicin-coated drug-loaded nanoparticles prepared in Comparative Example 2 is as follows: Fig.11 As shown. Fig.11 It can be seen that the coated drug-loaded nanoparticles can effectively release the drug and effectively retain the redox and pH dual response characteristics of the drug-loaded nanoparticles. The release rate in the 10mM GSH environment is faster than that in the 10μM GSH environment, and the release rate in the acidic environment is faster than that in the neutral environment.

[0083] Experimental Example 1: Performance Comparison

[0084] 1. Comparison between Example 1 and Comparative Example 1

[0085] The stability of the coated drug-loaded nanoparticles prepared in Example 1 and Comparative Example 1 was compared with the amount of millet polypeptide coated in the outer layer of the coated drug-loaded nanoparticles.

[0086] In Example 1, electrostatic adsorption and cross-linking act together to obtain the coated drug-loaded nanoparticles with good stability, and exhibited a steady and long-lasting drug release performance in PBS containing 10 μM GSH simulating normal human tissue.

[0087] In comparative example 1, electrostatic adsorption acts alone, and the amount of millet polypeptide wrapped in the outer layer of the obtained composite drug-loaded nanoparticles is less than that of the composite drug-loaded nanoparticles prepared in example 1.

[0088] The hydrated particle size of the drug-loaded nanoparticles prepared in Example 1 is 392.5 nm, while the hydrated particle size of the drug-loaded nanoparticles prepared in Comparative Example 1 is 367.2 nm).

[0089] 2. Comparison between Example 1 and Comparative Example 2

[0090] In Comparative Example 2, millet polypeptide and glutaraldehyde are added before freeze-drying. The wrapped drug-loaded nanoparticles have a compact structure and uniform particle size, but the wrapping effect is not as good as the wrapping effect of the wrapped drug-loaded nanoparticles obtained by re-adding millet polypeptide and glutaraldehyde after freeze-drying in Example 1 of the present invention. Compared with Example 1, the drug release rate of Comparative Example 2 is slowed down to a certain extent, but the sustained-release effect is not obvious. The in vitro drug release performance of the millet polypeptide-doxorubicin wrapped drug-loaded nanoparticles prepared in Comparative Example 2, the groups in the figure are PBS, ABS, PBS containing 10μM GSH, PBS containing 10mM GSH and ABS containing 10mM GSH, respectively. Fig.11 shown.

[0091] As can be seen from the above, in Example 1 of the present invention, millet polypeptide and glutaraldehyde are added for re-coating after freeze-drying, and the re-coating effect is good. The sustained-release effect of the obtained re-coated drug-loaded nanoparticles is more obvious than that of Comparative Example 2.

[0092] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.

[0093] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0094] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A coated sustained-release plant polypeptide drug-loaded nanoparticle, characterized in that: The coated sustained-release plant polypeptide drug-loaded nanoparticles are prepared by coating the plant polypeptide on the outer surface of the redox-sensitive plant polypeptide drug-loaded nanoparticles; The redox-sensitive plant polypeptide drug-loaded nanoparticles are prepared by using plant polypeptides and hydrophobic drugs as raw materials, introducing redox-sensitive monomers, using a mixed solution of alcohol and water as solvent, and under the action of a cross-linking agent.

2. The redox-sensitive plant polypeptide drug-loaded nanoparticles according to claim 1, characterized in that: In the coating, the mass ratio of the plant polypeptide to the redox-sensitive plant polypeptide drug-loaded nanoparticles is 3-6:

20.

3. The coated sustained-release plant polypeptide drug-loaded nanoparticles according to claim 1, characterized in that: The monomer of the redox sensitive structure includes at least one of cystamine hydrochloride, dithiodipropionic acid, diacrylamide, and dithiodicarboxylic acid; the plant polypeptide includes at least one of millet polypeptide, soybean polypeptide, peanut polypeptide, and corn polypeptide; the hydrophobic drug includes at least one of doxorubicin or its hydrochloride, erlotinib or its hydrochloride, curcumin or its hydrochloride, paclitaxel or its hydrochloride, methotrexate or its hydrochloride, and ibuprofen or its hydrochloride.

4. A method for preparing the coated sustained-release plant polypeptide drug-loaded nanoparticles according to any one of claims 1 to 3, characterized in that: The preparation method comprises the following steps: S1. Mix the plant polypeptide and the aqueous solution containing the redox-sensitive structural monomer, adjust the pH to 8.0-9.0, and continue the reaction until the reaction is complete to obtain a mixed system; S2, adding an alcohol solution of a hydrophobic drug to the mixed system and mixing well, and then adding a cross-linking agent until the reaction is complete to obtain a product; S3, removing the alcohol solution from the product and filtering it, centrifuging the remaining system, taking the supernatant, and freeze-drying it to obtain redox-sensitive plant polypeptide drug-loaded nanoparticles; S4, dissolving the redox-sensitive plant polypeptide drug-loaded nanoparticles in an alcohol solution, adding the plant polypeptide and the cross-linking agent, stirring evenly, and continuing the reaction; S5. After the reaction is completed, the insoluble matter is precipitated after the alcohol solution is removed. The remaining system after filtration is centrifuged and the supernatant is removed and freeze-dried to obtain the coated plant polypeptide drug-loaded nanoparticles.

5. The preparation method according to claim 4, characterized in that: In the step S4, the ratio of the volume of the cross-linking agent to the mass of the plant polypeptide is in the range of 2-4 μL / mg.

6. The preparation method according to claim 4, characterized in that: In the step S4, the cross-linking agent includes at least one of glutaraldehyde, glyoxal or o-phthalaldehyde.

7. The preparation method according to claim 4, characterized in that: In the step S4, the mass volume ratio of the redox-sensitive plant polypeptide drug-loaded nanoparticles to the alcohol solution is 9-11 mg / mL, the alcohol solution is ethanol, and the volume ratio of water to ethanol is 1:2-4.

8. The preparation method according to claim 4, characterized in that: When the hydrophobic drug is in the form of hydrochloride, the step S2 specifically comprises: Add the alcohol solution of the hydrophobic drug to the mixed system and mix well, then add the cross-linking agent, adjust the pH to 8.0-9.0 and continue the reaction until the reaction is complete to obtain the product.

Citation Information

Patent Citations

  • Soybean polypeptide-based nanoparticles with high curcumin load as well as pH driving preparation method and application of soybean polypeptide-based nanoparticles

    CN110897161A

  • Plant polypeptide drug loading system and preparation method thereof

    CN116570723A

  • Polypeptides comprising an ice-binding activity

    US20100312045A1

  • Pharmaceutical Composition Containing Lutein and Antioxidant for Treating and Preventing Human Disease

    US20150320699A1

  • Variants of Anti-freeze polypeptides

    WO2014202089A2